Delay in China's review time for drugs likely to continue; review predictability and transparency improve
This article was originally published in SRA
Executive Summary
Significant delays in 2011 by the Center for Drug Evaluation at China's State Food and Drug Administration in reviewing regulatory applications for medicines could continue for the foreseeable future, a senior industry professional has said.